GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxil Bio Ltd (TSXV:VXL) » Definitions » EV-to-Revenue

Vaxil Bio (TSXV:VXL) EV-to-Revenue : (As of Jun. 09, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Vaxil Bio EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Vaxil Bio's enterprise value is C$0.43 Mil. Vaxil Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.00 Mil. Therefore, Vaxil Bio's EV-to-Revenue for today is .

The historical rank and industry rank for Vaxil Bio's EV-to-Revenue or its related term are showing as below:

TSXV:VXL's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.86
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-09), Vaxil Bio's stock price is C$0.01. Vaxil Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.00. Therefore, Vaxil Bio's PS Ratio for today is .


Vaxil Bio EV-to-Revenue Historical Data

The historical data trend for Vaxil Bio's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxil Bio EV-to-Revenue Chart

Vaxil Bio Annual Data
Trend May14 May15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vaxil Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vaxil Bio's EV-to-Revenue

For the Biotechnology subindustry, Vaxil Bio's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxil Bio's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxil Bio's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Vaxil Bio's EV-to-Revenue falls into.



Vaxil Bio EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Vaxil Bio's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=0.432/0
=

Vaxil Bio's current Enterprise Value is C$0.43 Mil.
Vaxil Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vaxil Bio  (TSXV:VXL) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Vaxil Bio's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.01/0
=

Vaxil Bio's share price for today is C$0.01.
Vaxil Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vaxil Bio EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Vaxil Bio's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxil Bio (TSXV:VXL) Business Description

Traded in Other Exchanges
Address
C/O Kira Lynn, Bennet Jones LLP, 3400 One First Canadian Place, Toronto, ON, CAN, M5X 1A4
Vaxil Bio Ltd is an Israeli immunotherapy biotech company focused on a novel drug discovery and development platform based on Signal Peptides which the company deploys to fight infectious diseases and cancer.
Executives
Gadi Levin Director, Senior Officer

Vaxil Bio (TSXV:VXL) Headlines

No Headlines